相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
Yuying Liu et al.
SCIENCE IMMUNOLOGY (2020)
EARLY ADMINISTRATION OF TOCILIZUMAB (TOCI) FOR THE PREVENTION OF GRADE 4 CYTOKINE RELEASE SYNDROME (CRS) AFTER CD19-DIRECTED CAR T-CELL THERAPY (CTL019)
S. Kadauke et al.
CYTOTHERAPY (2019)
Clinical lessons learned from the first leg of the CAR T cell journey
Robbie G. Majzner et al.
NATURE MEDICINE (2019)
CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity
Ji Li et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Robert Q. Le et al.
ONCOLOGIST (2018)
A Retrospective Review of Tocilizumab for the Management of Blinatumomab (a Bispecific T Cell Engager)-Induced Cytokine Release Syndrome (CRS)
Jessica Choudhry et al.
BLOOD (2018)
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Kevin A. Hay et al.
BLOOD (2017)
Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function
Nathan Singh et al.
CYTOTHERAPY (2017)
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas
Michael Pishvaian et al.
CLINICAL COLORECTAL CANCER (2016)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia
Michael Durben et al.
MOLECULAR THERAPY (2015)
Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia
Simone M. C. Spoorenberg et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
David T. Teachey et al.
BLOOD (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Tocilizumab A Review of its Use in the Management of Rheumatoid Arthritis
Vicki Oldfield et al.
DRUGS (2009)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct
Christian Brandl et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
分享论文
